|
COPYRIGHT 2003 Adams Business Media
THE COMPANY
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes essential for cancer, cardiovascular diseases and viral infections. BioCryst uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry and computer modeling.
BioCryst's Approach to Building its Product Pipeline: Transforming Science into Products
BioCryst designs drug candidates using detailed knowledge of the structures of the active sites of targeted enzymes. The active site of an enzyme is the area into which a chemical or biological molecule fits to initiate a biochemical reaction. Enzymes make ideal drug targets as they mediate biochemical processes along disease pathways, are relatively easy to crystallize and have small active sites. BioCryst aims to design compounds that will fit in the active sites of enzymes and thereby interfere with the progression of disease. Using this approach, the company has successfully designed several product candidates for cancer, cardiovascular diseases and viral infections.
BUSINESS STRATEGY
BioCryst is growing its business through key strategic alliances. The company's corporate...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
